Cancer remains a formidable challenge in the field of therapy, necessitating the development of innovative therapeutic strategies. Conventional amino-acid-based engineering often falls short when it comes to finely tuning stability, selectivity, or mode of action. Leveraging our proprietary GCEngine platform, we enable the site-specific incorporation of non-canonical amino acids (ncAAs) through high-throughput development of orthogonal aaRS/tRNA pairs. This provides researchers and therapeutic developers with powerful molecular tools to precisely dissect cancer mechanisms and to develop the next generation of biotherapeutics.
Applications of ncAA Incorporation in Cancer Research
The precise incorporation of ncAAs into proteins unlocks unique capabilities that are reshaping cancer research and therapeutic development, including:
- Homogeneous Antibody–Drug Conjugates (ADCs)
Site-specific ncAA incorporation enables the generation of homogeneous ADCs with precisely defined drug-to-antibody ratios (DAR). This controlled conjugation helps improve therapeutic index by enhancing on-tumor efficacy while reducing off-target toxicity and pharmacokinetic variability.
- Proximity-Enabled Covalent Targeting
ncAAs with designed reactive functionalities can be installed at defined positions to enable proximity-enabled covalent binding to targets. This strategy can support the development of long-lasting, high-specificity protein therapeutics and modulators, particularly valuable for challenging or rapidly dissociating oncology targets.
- In Vivo Imaging and Mechanistic Studies
Site-specific installation of bioorthogonal handles, fluorescent dyes, or affinity tags facilitates high-sensitivity labeling of proteins in cancer cells and animal models. These tools allow real-time tracking of tumor progression, metastasis, drug distribution, and pharmacodynamics, providing mechanistic insights that are difficult to obtain with conventional methods.
Fig. 1 PD-1(FSY), a PD-1 variant bearing the ncAA FSY and acting as a proximity-enabled covalent inhibitor, showed superior tumor growth inhibition compared to wild-type PD-1 (WT) in a mouse tumor model. Adapted from Li et al., Cell (2020).
Our Services
Providing a comprehensive, integrated solution from discovery to validation, our proprietary GCEngine platform facilitates high-throughput identification and optimization of orthogonal aaRS/tRNA pairs tailored to specific ncAAs. Our expert services include rigorous in vitro validation of incorporation efficiency and fidelity, and extend to robust in vivo application support in relevant cellular and animal models of cancer. This integrated approach ensures the efficient translation of novel concepts into research tools and potential therapies. Whether you are optimizing an ADC conjugation site, building covalent biologics, or developing TME-activatable modalities, we design and validate ncAA-enabled constructs with quantified incorporation efficiency, fidelity, and functional readouts in relevant oncology models.
Cancer Research Services Powered by the GCEngine Platform
Tumor microenvironment (TME)-Responsive Peptide Library Development
Focused on the tumor microenvironment (TME), we develop diverse peptide libraries that incorporate ncAAs responsive to specific TME hallmarks such as pH gradients, elevated protease activity, or redox imbalance. This platform enables the discovery of TME-selective targeting ligands, activatable prodrugs with minimized off-tumor activity, and diagnostic probes, which enhance tumor selectivity and minimize off-target effects by specifically engaging cancer cells or modulating immune functions within the TME. By focusing on TME responsiveness, we help you improve tumor selectivity and reduce systemic toxicity at the molecular design stage.
ncAA Incorporated Peptide Therapy Development
Engineering therapeutic peptides with site-specific incorporation of ncAAs to overcome inherent limitations in stability, bioavailability, and target engagement. This allows for advanced modifications such as backbone stapling or cyclization using ncAAs to enhance structural stability and potency, introduction of protease-resistant motifs, precise conjugation of payloads, imaging agents, or half-life extenders, and the design of TME-activatable constructs, collectively advancing the potential of peptide-based cancer therapeutics and diagnostics.
ncAA-Engineered Protein Therapeutic Development
Utilizing site-specific ncAA incorporation to engineer next-generation protein therapeutics, including cytokines and immune modulators. Key services focus on fine-tuning activity and exposure of cytokines or immune modulators for improved therapeutic index, incorporating handles for controlled bioconjugation, embedding stability-enhancing and aggregation resistance modifications, generating TME-activated agonists/antagonists, and creating novel protein formats with customized activity and reduced immunogenicity.
ncAA Incorporated Antibody Therapeutic Development
Antibodies and antibody–drug conjugates (ADCs) are central to modern cancer treatment, but conventional conjugation often produces heterogeneous mixtures with variable drug-to-antibody ratios and unpredictable behavior. Complex formats such as dual-payload ADCs and multispecific antibodies are also challenging to access using traditional technologies. Site-specific ncAA incorporation facilitates the creation of homogeneous multispecific antibodies, controlled Fc glycoengineering for fine-tuned effector function, site-specific conjugation for homogeneous DAR or dual-payload ADCs, and the development of stability or activity optimized variants for complex oncology targets.
Contact Us
Empowering your cancer research and therapeutic development, we provide reliable, end-to-end solutions that accelerate timelines and de-risk project progression through our cutting-edge GCE technology and specialized expertise. As a trusted partner of your R&D team, we collaborate closely to overcome critical challenges in oncology, from target validation to therapeutic development to mechanistic understanding. Explore how our GCEngine platform can accelerate your next cancer breakthrough. Contact our scientific team for a detailed consultation.
Reference
- Li, Qingke et al. "Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics." Cell 182.1 (2020): 85-97.e16.
